21 / 136
Review of Group Entities
19
Apex develops, manufactures, markets and distributes pharmaceuticals, diagnostic products and equipment,
consumer healthcare products and orthopaedic devices. It has operations in Malaysia, Singapore, Vietnam and
Myanmar (Burma) and is publicly listed on the Main Board of Bursa Malaysia.
For the six months ended 30 June 2016 Apex generated revenue of $98.1 million, an increase of 6.4% over the
$92.2 million for the previous corresponding six month period. Net profit after tax was $6.5 million, an increase
of 23.7% compared to first half of 2015.
Apex paid an interim dividend of 1.8 cents per share for the six months ended 30 June 2016, an increase of 6.8%
compared to the prior year’s interim dividend.
WHSP has equity accounted Apex’s result for the 12 months to 30 June 2016. Apex contributed a net profit of
$3.4 million to the Group (2015: $3.4 million).
Apex Healthcare Berhad
Associated entity:
30.3% held
Dividends paid to WHSP:
$1.3 million
Total Market Capitalisation:
$149 million
Value of WHSP’s Holding:
$45 million
Listed on Bursa Malaysia, code:
APEX MK
DIVIDENDPAID
TOTHEGROUP
INCREASED
6.8%